NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCATS E-218-2021-0-US-02 SMALL MOLECULE AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF US National Stage 18/837,100 Pending
NIAID E-083-2017-0-US-06 GLYCAN-MASKED ENGINEERED OUTER DOMAINS OF HIV-1 GP120 AND THEIR USE US CON 18/793,025 Pending
NICHD E-026-2019-0-US-02 POLYPEPTIDES, NUCLEIC ACID MOLECULES, COMPOSITIONS, AND RELATED METHODS US DIV 18/786,697 Pending
NCI E-040-2012-0-KR-01 CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN KR DIV 2024-7025571 Pending
NIBIB E-157-2023-0-PC-01 METHOD AND SYSTEM FOR RAPID SPECTRAL UNMIXING USING SPECTRALLY INTERPOLATED BACKGROUND REDUCTION PCT PCT PCT/US2024/039976 Pending
NHLBI E-035-2022-0-US-02 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) US National Stage 18/833,627 Pending
NHLBI E-035-2022-0-JP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) JP National Stage 2024-544466 Pending
NCI E-042-2014-0-AU-01 Chimeric Antigen Receptors Targeting CD-19 AU DIV 2024205043 Pending
NCI E-025-2022-0-AU-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF AU National Stage 2023221836 Pending
NCI E-237-2017-2-CR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0303 Pending
NHLBI E-035-2022-0-CA-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) CA National Stage 3243219 Pending
NCI E-237-2017-2-CR-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0302 Pending
NCI E-237-2017-2-CR-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR DIV 2024-0301 Pending
NIA E-024-2022-0-US-02 GINGERENONE A PRODRUGS AS SENOTHERAPEUTICS AND METHODS OF USE US National Stage 18/832,248 Pending
NIA E-024-2022-0-US-03 GINGERENONE A PRODRUGS AS SENOTHERAPEUTICS AND METHODS OF USE US CIP 18/780,981 Pending
NHLBI E-035-2022-0-EP-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) EP National Stage 23707534.6 Pending
NHLBI E-035-2022-0-IL-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) IL National Stage 314428 Pending
NCI E-056-2023-0-PCT-01 IDENTIFICATION OF NOVEL SEQUENCES OF THE ERVMER34-1 HUMAN ENDOGENOUS RETROVIRAL SEQUENCE FAMILY, AND MODIFICATION OF THOSE SEQUENCES FOR A MORE EFFECTIVE ANTI-CANCER VACCINE AND OTHER POTENTIAL ANTI-CANCER THERAPIES PCT PCT PCT/US2024/039057 Pending
NIAID E-165-2023-0-PC-02 BISPECIFIC ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES PCT PCT PCT/US2024/038583 Pending
NCI E-202-2023-0-PC-01 KINASE INHIBITORS PCT PCT PCT/US2024/038376 Pending
NIDDK E-162-2023-0-PC-01 5-HT2B SEROTONIN RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF PCT PCT COMB PCT/US2024/038286 Pending
NHLBI E-342-2013-0-US-02 Human IPSC-derived Vascular-related And Hematopoetic Cells For Therapies And Toxicology/drug Screenings US CON 18/775,257 Pending
NCI E-045-2022-0-US-02 METHOD OF HUMAN LEUKOCYTE ANTIGEN LOSS OF HETEROZYGOSITY DETECTION IN LIQUID BIOPSIES US National Stage 18/729,138 Pending
NCI E-133-2016-0-JP-13 FLT3-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME JP DIV 2024-112931 Pending
NCI E-125-2023-0-PC-01 FULLY HUMAN MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AGAINST CD276 FOR THE TREATMENT OF SOLID TUMORS PCT PCT PCT/US2024/037349 Pending
NCI E-188-2023-0-PC-01 HUMANIZED 40H3 ANTIBODY PCT PCT PCT/US2024/037091 Pending
NCI E-051-2022-0-US-02 METHODS OF PREDICTING PATIENT TREATMENT RESPONSE AND RESISTANCE VIA SINGLE-CELL TRANSCRIPTOMICS OF THEIR TUMORS US National Stage 18/727,094 Pending
NCI E-184-2009-0-US-05 Combination Immunotherapy Compositions And Methods US CON 18/764,645 Pending
NCATS E-057-2022-0-US-02 ESTRADIOL PRODRUGS AND METHODS OF USE THEREOF US National Stage 18/726,051 Pending
NIDDK E-051-2021-0-EP-02 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS EP DIV 24185703.6 Pending
NIAAA E-190-2021-0-EP-01 Thiol-moeity Containing Cannabinoid Receptor Modulating Compounds EP National Stage 22847074.6 Pending
NIBIB E-054-2018-0-CN-01 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER CN DIV 2024108723712 Pending
NIAID E-297-2016-2-US-01 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES US CON 18/758,660 Pending
NCATS E-097-2023-0-PC-01 POTENT AND SELECTIVE DOPAMINE D3 ANTAGONISTS PCT PCT PCT/US2024/036149 Pending
NINDS E-186-2023-1-PC-01 Use of Iron Chelators for Treating Stuttering PCT PCT PCT/US2024/036062 Pending
NCI E-046-2022-0-JP-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER JP National Stage 2024-539628 Pending
NICHD E-184-2021-0-RU-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO RU National Stage 2024118060 Pending
NIAID E-080-2013-0-US-02 ATTENUATION OF HUMAN RESPIRATORY SYNCYTIAL VIRUS BY GENOME SCALE CODON-PAIR DEOPTIMIZATION US CON 18/756,709 Pending
NHGRI E-034-2022-0-EP-01 IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA EP National Stage 22856962.0 Pending
NEI E-076-2023-0-PC-01 SHIPPING CONTAINER FOR SYSTEM SUPPORTING LIVE CELLS PCT PCT PCT/US2024/035854 Pending
NIDDK E-138-2017-0-EP-01 COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS EP DIV 24184468.7 Pending
NCI E-046-2022-0-EP-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER EP National Stage 22854399.7 Pending
NCATS E-118-2019-0-EP-01 SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF EP DIV 24184424.0 Pending
NCI E-046-2022-0-AU-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY AGAINST CANCER AU National Stage 2022425620 Pending
NIAID E-018-2018-0-TW-01 CHIMERIC VECTORS TW DIV 113123612 Pending
NIAID E-096-2023-0-PC-01 NOVEL MALARIA VACCINE COMPRISING AMA1 AND RON2 ANTIGENS PCT PCT PCT/US2024/035244 Pending
NCI E-094-2018-0-CN-01 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF CN DIV 202410809055.0 Pending
NHGRI E-034-2022-0-US-02 GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA US National Stage 18/723,020 Pending
NCATS E-022-2022-0-US-02 METHODS AND SYSTEMS FOR ANALYZING TARGET ENGAGEMENT DATA
FROM BIOLOGICAL ASSAYS 		US National Stage 18/722,188 Pending
NICHD E-184-2021-0-KR-01 LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO KR National Stage 2024-7020525 Pending